Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI)

Sponsor
Sunnybrook Health Sciences Centre (Other)
Overall Status
Terminated
CT.gov ID
NCT01029106
Collaborator
Johnson & Johnson (Industry)
125
1

Study Details

Study Description

Brief Summary

This is a prospective, non-randomized, observational, multicentre (5 sites) study in which subjects that have surgically-correctable Stress Urinary Incontinence undergo a TVT SECUR operative procedure.

The study will collect preoperative urologic testing, medical history, and subject quality of life patient questionnaires, Intraoperative procedural data will be collected.

Postoperative complications, urologic, testing, and subject questionnaires will be collected at intervals up to 24 months. The anatomic position of the device will be characterize by transvaginal ultrasound testing.

To determine the rate and/or improvement rate of patients who have received the Gynecare Secur device after 12 months and after 24 months.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Gynecare TVT Secur

Study Design

Study Type:
Observational
Anticipated Enrollment :
125 participants
Time Perspective:
Prospective
Official Title:
Prospective, Non-Randomized, Observational, Multicentre, Study of the TVT Secur in the Surgical Management of Women With Stress Urinary Incontinence
Study Start Date :
Sep 1, 2009
Anticipated Primary Completion Date :
Sep 1, 2012

Outcome Measures

Primary Outcome Measures

  1. The primary endpoints are the cure/improvement rate in the cohort at 12 months. [12 months]

Secondary Outcome Measures

  1. Distribution of percentage of subjects having a decrease of pad weight as compared to baseline [24 months]

  2. Decrease in number of pads used within a 24-hour period as compared to baseline [24 months]

  3. Change in patient questionnaires from baseline [24 months]

  4. Change in the sling position on transvaginal ultrasound [24 months]

  5. Cure/improvement rate at 24 months [24 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:

To be considered eligible to participate in this study, subjects must meet the following requirements:

  1. Subject has agreed to undergo surgical implantation of the TVT SECUR System

  2. Subject has the complaint of SUI for at least 6 months prior to the Preoperative Evaluation Visit.

  3. Subject has confirmed SUI resulting from urethral hypermobility on cough stress testing.

  4. Subject has at least 4 gm of urine leakage on 1-hour pad testing during the Preoperative Screening Visit.

  5. Subject is at least 18 years of age to maximum of 85 years of age

  6. Subject is willing and able to give written informed consent prior to any study related procedures.

  7. Subject is willing to return for follow-up evaluation and questionnaire completion at 4-6 weeks, and at 3, 6, 12 and 24 month follow-ups.

  8. Subject is willing to undergo transvaginal ultrasound evaluation at the 4 weeks and 12 month follow-up visit.

Exclusion Criteria:

Subjects will not be eligible for entry into the study if they meet one of the following criteria:

  1. Subject is pregnant.

  2. Subject has had any previous synthetic sub-urethral sling procedure.

  3. Subject has current urinary tract or vaginal infections.

  4. Subject has blood coagulation disorders.

  5. Subject has a compromised immune system or any other conditions that would compromise healing.

  6. Subject has upper urinary tract obstruction.

  7. Subject is unwilling to provide written informed consent.

  8. Subject is unwilling or unable to return for evaluation at 4-6 weeks, and at 3, 6, 12, and 24 months.

  9. Subject has uncontrolled detrusor overactivity.

  10. Subject has PVR greater than 100 cc.

  11. Subject has Peak Flow Rate less than 10 ml/sec.

  12. Subject has urethral diverticulum.

  13. Subject has significant pelvic organ prolapse (Grade III/IV) requiring surgical treatment.

  14. Subject has had radiation therapy to the pelvic area at any time.

  15. Subject has current or active history of pelvic cancer.

  16. Subject who in the opinion of the investigator is unable and/or unlikely to comprehend the nature, scope and possible consequences of the study and to follow the study procedures and instructions and complete all study related measurements.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sunnybrook Health Sciences Centre Toronto Ontario Canada M4N 3M5

Sponsors and Collaborators

  • Sunnybrook Health Sciences Centre
  • Johnson & Johnson

Investigators

  • Principal Investigator: Sender Herschorn, MD, Sunnybrook Health Sciences Centre

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01029106
Other Study ID Numbers:
  • TVTSecur
  • 047-2009
First Posted:
Dec 9, 2009
Last Update Posted:
Jul 28, 2011
Last Verified:
Jul 1, 2011

Study Results

No Results Posted as of Jul 28, 2011